Landos Biopharma announces publication in Scientific



BLACKSBURG, Va., Oct. 06, 2021 (GLOBE NEWSWIRE) – Landos Biopharma, Inc. (NASDAQ: LABP), an advanced clinical stage biopharmaceutical company using its LANCE® The advanced AI platform to discover and develop new therapies for patients with autoimmune diseases, today announced the publication of a peer-reviewed article titled “First-in-class topical therapeutic omilancor improves disease severity and inflammation through activation of the LANCL2 pathway in psoriasis ”in Scientific reports. The peer-reviewed publication demonstrates the therapeutic efficacy of omilancor in animal models of psoriasis.

“The results published in Scientific reports present for the first time the therapeutic potential of omilancor as a topical treatment for psoriasis, a chronic autoimmune disease affecting more than 100 million patients worldwide ”, said Dr. Josep Bassaganya-Riera, Chairman and CEO by Landos. “Omilancor is currently in clinical development for three indications: ulcerative colitis, Crohn’s disease and eosinophilic esophagitis. Demonstration of the therapeutic efficacy of a topical formulation of omilancor in non-gastrointestinal indications further validates the activation of LANCL2 and expands the therapeutic potential of the LANCE AI platform and the expandable inflammation and inflammation pipeline. ‘immunology. The topical formulation of omilancor has the potential to offer patients a novel nonsteroidal treatment for psoriasis taking advantage of the innovative mechanism of action based on LANCL2 and could be a safe and effective long-term treatment option for this skin condition. widespread and often debilitating.

The Scientific reports the article reports new results from two preclinical models of psoriasis in which administration of omilancor reduced disease severity topically, resulting in a 60% reduction in area score and severity index psoriasis (PASI), a double decrease in thickness and scaling of the skin and more than 50% reduction in inflammatory reactions in the lymph nodes and spleen. In addition, activation of the LANCL2 pathway by omilancor via the engagement of immunometabolic mechanisms led to a significant downregulation of pro-inflammatory markers, a decrease in the induction of Th17 responses and the activation of cells of skin without inducing systemic immune suppression. Overall, topical treatment with omilancor helped maintain healthy skin composition and structure and demonstrated the potential to restore tissue homeostasis.

The published Scientific reports The article will be available in the “Publications” section of the Company’s website at

About psoriasis
Psoriasis is a skin disorder that typically manifests as plaque psoriasis, in which the skin thickens and takes on a scaly appearance due to overproliferation and deregulated differentiation of skin cells. This overproliferation and abnormal differentiation results from chronic inflammation of the skin, associated with the infiltration and activation of key inflammatory subsets, such as dendritic cells, Th17 cells, and neutrophils. This often results in persistent itching and rashes and has a significant impact on the quality of life of patients. In terms of management, topical corticosteroids or immunosuppressants are generally used. For more severe cases or those with psoriatic arthritis, systemic immunosuppressants (methotrexate, cyclosporine) or biological agents targeting TNF or the IL-12 / -23 pathway are prescribed. Like their use in other autoimmune diseases, biologics and immunosuppressants require monitoring of liver function and immunosuppression, as these agents have been associated with increased risks of infections and cancers. There is an urgent need to develop an alternative first-line therapy.

About Omilancor
Discovered using LANCE owner of Landos® An advanced AI platform, omilancor is a new investigational small molecule, oral, gut-restricted drug that targets the Lanthionine Synthetase C-Like 2 (LANCL2) pathway impacting the gastrointestinal tract. LANCL2 plays an important role in the immunoregulatory process. By activating the LANCL2 pathway and modulating the interactions between immunological and metabolic signals in immune cells, omilancor is designed to create a favorable regulatory microenvironment in the gut, decreasing the production of key inflammatory mediators and improving the function of regulatory T cells. (Treg) within the site of inflammation. Landos reported continued positive phase 2 results from omilancor evaluating ulcerative colitis (UC) patients in 2021 and, following a positive end of phase 2 meeting, initiated site feasibility studies for its clinical program Global Phase 3 Pivotal (PACIFY I and PACIFY II) in patients with mild to moderately active UC. In addition, Landos has launched two phase 2 trials of omilancor in patients with Crohn’s disease, with the first results for the first of these trials, involving 150 patients, expected in the first half of 2022. Landos also plans to launch phase 1 studies in eosinophilic esophagitis in 2022. Omilancor is also being investigated in a topical formulation for psoriasis and atopic dermatitis.

About Landos Biopharma
Landos Biopharma is an advanced clinical biopharmaceutical company using its LANCE® Advanced AI platform to discover and develop new therapies for patients with autoimmune diseases. Using the LANCE® platform, the Company has discovered new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. Landos Biopharma has 17 active development programs targeting these new pathways at the interface of immunity and metabolism. Its lead product candidate, omilancor, targets the LANCL2 pathway and is a new, potentially first-in-class, oral, gut-restricted, small-molecule drug currently in preparation for global Phase 3 pivotal trials for the treatment of colitis. ulcerative, in two Phase 2 trials in Crohn’s disease, and is expected to initiate Phase 1 studies in eosinophilic esophagitis in 2022. Omilancor is also being investigated in a topical formulation for psoriasis and atopic dermatitis. Landos has another new small molecule drug candidate for oral restricted use, NX-13, which is being investigated in an active phase 1b trial in ulcerative colitis. NX-13 targets the NLRX1 pathway. Landos’ sixth new product candidate, LABP-104, will enter Phase 1 clinical trials in healthy volunteers in the fourth quarter of 2021. Other product candidates are under development for the treatment of lupus nephritis, Rheumatoid arthritis, multiple sclerosis, Alzheimer’s disease, alcoholic steatohepatitis (NASH), asthma, chronic obstructive pulmonary disease (COPD), diabetes and diabetic nephropathy. For more information, please visit

Caution regarding forward-looking statements
Statements in this press release regarding the future expectations, plans and prospects of Landos Biopharma, Inc. (the “Company”), including statements regarding the Company’s strategy, clinical development and regulatory plans for its product candidates, the Company’s planned milestones and future expectations and the Company’s plans and prospects and other statements containing the words “anticipate”, “, strategy constitute forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements due to various important factors, including: uncertainties inherent in the initiation and registration of future clinical trials, expectations of expansion of ongoing clinical trials, availability and the timing of ongoing clinical trial data, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company’s product candidates and other similar risks. The risks relating to the Company’s business are described in detail in its filings with the Securities and Exchange Commission (“SEC”), including its annual reports on Form 10-K and quarterly reports on Form 10-Q, which are available on the SEC’s website at www. Additional information will be made available in other documents filed by the Company from time to time with the SEC. These risks may be magnified by the impacts of the COVID-19 pandemic. Further, the forward-looking statements included in this press release represent the views of the Company only as of the date hereof. The Company expects subsequent events and developments to cause a change in the outlook of the Company. However, although the Company may choose to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be taken as representing the views of the Company as of a date subsequent to the date hereof.

Marek Ciszewski, JD
Landos Biopharma
[email protected]

Michael K. Levitan (investors)
Solebury Trout
[email protected]

Hannah Gendel (media)
Solebury Trout
[email protected]


Leave A Reply

Your email address will not be published.